Pfizer News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Pfizer from all sources in a single place.

Pfizer Ltd.

09 Jan 2026, 12:04PM

4871.80

1.37%

Company Update

Pfizer Ltd - 500680 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Please find enclosed herewith the certificate confirming compliance with Regulation 74(5) of the SEBI (DP) Regulations, 2018, for the quarter ended December, 31, 2025.

pdf

Pfizer Ltd.

29 Dec 2025

4871.80

1.37%

SAST

Pfizer Ltd - 500680 - Closure of Trading Window

BSE India

This is to inform you that the trading window for trading in shares of the Company shall remain closed from Wednesday, December 31, 2025 (close of business) till 48 hours after the financial results are made public.

pdf

Pfizer Ltd.

28 Dec 2025

4871.80

1.37%

Corp. Note

Pfizer Ltd - 500680 - Disclosure under Regulation 30A of LODR

BSE India

Intimation pursuant to Regulation 30 of SEBI LODR regarding receipt of an order levying penalty from GST Authorities.

pdf

Pfizer Ltd.

24 Dec 2025

4871.80

1.37%

Company Update

Pfizer Ltd - 500680 - Intimation Pursuant To Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Intimation pursuant to Regulation 30 of SEBI LODR regarding receipt of an order levying penalty from GST Authorities.

pdf

Pfizer Ltd.

23 Dec 2025

4871.80

1.37%

Company Update

Pfizer Ltd - 500680 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Intimation regarding change in Senior Management Personnel of the Company - Resignation of Ms. Aditi Mehta - Category Lead, Vaccines.

pdf

Pfizer Ltd.

19 Dec 2025

4871.80

1.37%

Pfizer, Cipla sign exclusive marketing, distribution deal for 4 brands

Business Standard

Cipla Ltd has inked an exclusive agreement with Pfizer India to market, distribute, and sell the latter's four brands across the country. Under the agreement, Cipla now has the sole right to market, distribute and sell the cough syrup Corex Dx and Corex LS, the non-steroidal anti-inflammatory drug (NSAID) Dolonex, proton pump inhibitor (PPI) Neksium and the oral antibiotic Dalacin C in India, the two companies said in a joint statement on Friday. Pfizer will continue to manufacture, source, and supply these medicines to Cipla for India, they added. It is the first partnership between Pfizer and Cipla in India. The agreement aims to make Pfizer's medicines widely available across India by combining its well-established portfolio with Cipla's deep market reach, the statement said. Pfizer India Country President Meenakshi Nevatia said the partnership with Cipla will help expand the reach of its medicines to patients. "With Pfizer's legacy of breakthroughs, quality and innovation, and

Pfizer Ltd. has an average target of 6100.00 from 1 broker.

Pfizer Ltd.

19 Dec 2025

4871.80

1.37%

Company Update

Pfizer Ltd - 500680 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release in respect of an exclusive Supply & Marketing Arrangement with Cipla Limited for certain brands.

pdf

Pfizer Ltd.

19 Dec 2025

4871.80

1.37%

Company Update

Pfizer Ltd - 500680 - Exclusive Supply And Marketing Agreement With Cipla Limited For Certain Products.

BSE India

Exclusive Supply and Marketing Arrangement with Cipla Limited for Pfizer Limited''s Brands Corex Dx, Corex LS, Dolonex and Neksium.

pdf

Pfizer Ltd.

07 Dec 2025

4871.80

1.37%

Eli Lilly, Pfizer drugs added to China's first private insurance list

Business Standard

As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the inclusion of these drugs may ease the burden on state medical insurance